AEON Biopharma (AEON) Corporate presentation summary

Market opportunity and competitive landscape

• U.S. therapeutic neurotoxin market projected to grow from $3.5B in 2026 to $5.1B by 2031, with BOTOX® holding over 90% share due to full-label access and lack of clinically substitutable alternatives.

• Competitors are limited by restricted labels, operational complexity, and inability to match BOTOX®'s broad indications.

• Payers and providers face economic friction and limited cost-control levers due to BOTOX®'s dominance.

Product strategy and differentiation

• ABP-450 is developed as a true biosimilar to BOTOX®, matching label, dosing, dilution, workflow, and outcomes.

• Full-label parity and clinical equivalence are designed to enable immediate market competition and large-scale switching.

• Operational simplicity and biosimilarity lower switching barriers for physicians and payers.

Scientific and manufacturing foundation

• ABP-450 is based on the same 900kDa toxin as Jeuveau®, with 100% amino acid sequence identity and genetic/formulation parity to BOTOX®.

• Manufactured by Daewoong Pharmaceuticals in a globally validated, FDA- and EMA-approved facility.

• Demonstrates highly similar potency and clinical dose predictability across independent assays.